These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 37191564

  • 1. Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal.
    Santos M, Sequeira J, Abreu P, Guerreiro R, Santos M, Ferreira J, Brum M, Ladeira F, Leitão L, Dias R, Sá MJ, Salgado V, Capela C, de Sá J.
    Clin Neuropharmacol; ; 46(3):105-111. PubMed ID: 37191564
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    Zanetta C, Rocca MA, Meani A, Martinelli V, Ferrè L, Moiola L, Filippi M.
    J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
    [Abstract] [Full Text] [Related]

  • 3. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
    Rauma I, Viitala M, Kuusisto H, Atula S, Sipilä JOT, Ryytty M, Soilu-Hänninen M, Järvinen E.
    Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129
    [Abstract] [Full Text] [Related]

  • 7. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 8. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
    Rolfes L, Pfeuffer S, Huntemann N, Schmidt M, Su C, Skuljec J, Aslan D, Hackert J, Kleinschnitz K, Hagenacker T, Pawlitzki M, Ruck T, Kleinschnitz C, Meuth SG, Pul R.
    Mult Scler Relat Disord; 2022 Aug 25; 64():103931. PubMed ID: 35690010
    [Abstract] [Full Text] [Related]

  • 9. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
    Negrotto L, Iut VC, Etchepare A, D'Eramo M, Grinspan A, Assefi A.
    Mult Scler Relat Disord; 2022 Dec 25; 68():104403. PubMed ID: 36544327
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
    Rau D, Müller B, Übler S.
    Adv Ther; 2023 Dec 25; 40(12):5547-5556. PubMed ID: 37776477
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine.
    Al-Hashel J, Ahmed SF, AlMojel M, Alroughani R.
    Clin Neurol Neurosurg; 2023 Sep 25; 232():107885. PubMed ID: 37459794
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
    Pfeuffer S, Rolfes L, Hackert J, Kleinschnitz K, Ruck T, Wiendl H, Klotz L, Kleinschnitz C, Meuth SG, Pul R.
    Mult Scler; 2022 Feb 25; 28(2):257-268. PubMed ID: 33975489
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA, Katz J, Robertson D, Hayward B, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ.
    Neurodegener Dis Manag; 2021 Apr 25; 11(2):99-111. PubMed ID: 33517769
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.